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Background: Biliary tract cancers are uncommon tumors with a poor prognosis and most patients present with
invasive and inoperable disease at diagnosis. Chemotherapy represents a palliative treatment, with poor response
rates and a median survival of less than 6 months. Oxaliplatin and gemcitabine have shown an interesting activity as
single agents in this group of patients.
Patients and methods: We carried out a multicenter phase II study to evaluate the efficacy and safety of combined
oxaliplatin and gemcitabine in locally advanced and metastatic biliary tract carcinoma. The schedule of chemotherapy
included oxaliplatin 100 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on days 1 and 8, every 21 days.
Results: All the 24 patients were evaluable for response and toxicity. According to RECIST criteria we observed one
complete response and 11 partial responses for an overall response rate of 50%. Overall survival for all the patients on
study was 12 months (range 2–30). According to WHO criteria, three patients (12.5%) suffered grade 3 neutropenia
and three patients (12.5%) grade 3 thrombocytopenia. Only two patients (8%) suffered grade 3 neuropathy.
Conclusions: Oxaliplatin and gemcitabine chemotherapy seems to be effective with a favorable safety profile in
first-line chemotherapy of advanced biliary tract cancers.
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introduction
Biliary tract cancers are uncommon tumors with a poor
prognosis and most patients present with invasive and
inoperable disease at diagnosis [1]. Chemotherapy represents
a palliative treatment, but single or combination-drug schedules
have demonstrated poor response rates with a median survival
of less than 6 months [2]. Fluoropyrimidines have been
considered the basis of palliative chemotherapy despite response
rates in the range of 0%–10%.. Older combination
chemotherapy, including fluorouracil (FU), has not
demonstrated a clear superiority over single-agent FU but have
resulted in added toxicity [3, 4]. A number of recent phase II
trials using newer chemotherapeutic agents suggest a level of
chemosensitivity not previously seen. Gemcitabine, newer FU
regimens, capecitabine and platinum analogs all seem to be
active and, perhaps, are more active in combinations [5]. The
larger phase II trials report objective response rates (ORRs)
ranging from 15% to 45% [6]. Differences in response rates
between gall-bladder and cholangiocarcinoma have not been
seen; however, some series report poorer overall survival for
patients with gall-bladder cancer compared with
cholangiocarcinoma [7].
The nucleoside analog gemcitabine is a chemotherapeutic
agent with a favorable therapeutic profile. It has shown ORRs
ranging from 15% to 35% in a number of phase II trials in
biliary cancers and seems consistently active and well tolerated
as a single agent [8–11]. Among the newest drugs, significant
anti-tumor activity, at a very low level of toxicity in the
treatment of gastric and colon cancer has been more recently
shown for the novel diaminocyclohexane (DACH) carrier
ligand-based/platinum compound, oxaliplatin (OX), alone or in
combination with 5-FU and FA (FUFA) [12]. Preliminary
results of phase I and II trials of gemcitabine in association with
oxaliplatin in patients with advanced biliary tract carcinoma
have shown a good toxicity/efficacy ratio for the combination
[13–16]. On the basis of these data we carried out a phase II
study of combination therapy with oxaliplatin 100 mg/m2 on
day 1 and gemcitabine 1000 mg/m2 on days 1 and 8 every
3 weeks in patients with advanced biliary tract carcinoma.
patients and methods
Patients were eligible if they had pathologically proven, measurable,
unresectable, locally advanced or metastatic adenocarcinoma arising from
the intra- and extrahepatic biliary ducts or gall-bladder. No prior
chemotherapy for advanced disease was allowed. Additional inclusion
criteria included age 18 years, Eastern Cooperative Oncology Group
(ECOG) [17] performance status £2, and adequate organ functions
[neutrophils 1.5 · 10/l, platelets 100 · 10/l, serum creatinine 160 lmol/l or
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actual or calculated creatinine clearance 60 ml/min, ALT 5 · upper limit of
normal (ULN), and total bilirubin 3 · ULN and stable for 2 weeks]. Written
informed consent was obtained from each patient. The protocol and the
informed consent form were approved by the local ethical committee.
treatment plan
Patients were treated on a 3-week cycle, with dosing based on the
recommended dose from phase I and II studies in literature [18–20].
Gemcitabine was administered intravenously over 30 min on days 1 and 8 of
each cycle at a fixed dose of 1000 mg/m2. Oxaliplatin was administered
intravenously over 3 h on day 1 at 100 mg/m2 after gemcitabine infusion.
Treatment was continued until progression, unacceptable toxicity, or
withdrawal of patient consent. Adverse events were recorded according to
the National Cancer Institute Common Toxicity Criteria [21]. Dose
adjustments and delays were allowed for each drug. Gemcitabine and
oxaliplatin doses were reduced by 25% on all subsequent cycles for febrile
neutropenia, grade 4 hematologic toxicity lasting for more than 7 days, or
bleeding-associated thrombocytopenia. Chemotherapy doses were reduced
by 25% on day 8 for an absolute neutrophil count of 500–1000/ll or
a platelet count of 50 000 to 100 000/ll. For patients on progression and
with good performance status, a 5-FU based single-agent chemotherapy was
planned as second-line chemotherapy.
assessment
Tumor response was assessed using Response Evaluation Criteria in Solid
Tumors [22] with computer tomography scans at baseline and every three
cycles of treatment. Responses were confirmed by computed tomography at
least 4 weeks later. The primary investigation of interest was the tumor ORR,
with secondary investigations including overall and progression-free
survival, safety and tolerability of this treatment. Summary statistics, such as
the median and range, were used to describe the patient sample. The
Kaplan–Meier method [23] was used to estimate overall and progression-
free survival outcomes. Survival curves were compared with the log-rank
test. All tests were two-sided, and a P < 0.05 was considered statistically
significant.
results
Twenty-four patients (15 males and nine females) with
advanced biliary cancer were enrolled between October 2002
and January 2004. Nine patients had carcinoma of the gall-
bladder and 15 had cholangiocarcinoma or extrahepatic biliary
system disease. Demographics and other baseline characteristics
are listed in Table 1. Thirteen patients had a PS = 0, seven
patients had a PS = 1 and four patients had a PS = 2. Ten
patients had metastatic disease, six of which experienced disease
recurrence after a prior resection with curative intent. Eight
patients had undergone exploratory laparotomy to determine
unresectability, whereas the remaining 16 were clearly
unresectable based on radiological evidence of distant metastatic
disease. Most patients had a good performance status at the start
of therapy (ECOG performance status of 0–1 in 20 patients) and
the median age was 68 years (range 59–73 years). All patients
were assessable for efficacy and toxicity analysis. Over 120 cycles
of Gem Ox chemotherapy were delivered, with a median of four
cycles per patient (range one to eight cycles). Across all cycles,
patients received more than 90% of initial prescribed
chemotherapy. The primary reason for discontinuing treatment
was progressive disease (20/24 patients who completed
treatment). Two patients requested a break and two
discontinuations were at the physician’s discretion because of
other comorbidities. Median follow-up time per patient was 13
months (range 1.1–30 months). According to RECIST criteria
we observed one complete response (CR) and 11 partial
responses (PR) for an overall response rate of 50%. Five
stable disease (SD) and seven progressive disease (PD) also
occurred. Table 2 shows the responses divided for gall-bladder
cancer and cholangiocarcinoma. The responders (PR + CR)
demonstrated a TTP of 10 months (range 6–24) and an overall
survival of 18 months (range 6–30), while the overall survival
for all the patients in the study was 12 months (range 2–30).
Figures 1 and 2 demonstrate the progression-free survival and
overall survival curves for patients with gall-bladder or bile
ducts cancers: there was no statistically significant difference.
Of note, 11/24 patients received a second-line 5-FU based
chemotherapy after progression of disease. Two patients with
locally advanced disease with objective response underwent
surgical procedure.
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Figure 1. Progression-free survival for patients with gall-bladder cancer
(Group 1) and bile ducts cancers (group 2).
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Figure 2. Overall survival for patients with gall-bladder cancer (Group 1)
and bile ducts cancers (group 2).
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Table 3 reports the most important toxicities. According to
WHO criteria, three patients (12.5%) suffered grade 3
neutropenia and three patients (12.5%) grade 3
thrombocytopenia. One-third of patients developed grade 1–2
peripheral neuropathy and only two patients (8%) suffered
grade 3 neuropathy. Grade 1–2 nausea/vomiting was present in
six patients (25%) and only one patient (4%) suffered grade 3
nausea/vomiting. Grade 3 fatigue was observed in five patients
(20%) and mild fatigue during treatment (grade 1–2) was
reported in 45% of patients. There was no difference in toxicity
between patients with gall-bladder cancers and patients with
bile duct cancers. No treatment-related liver toxicity was
observed in any of the patients on this study. This combination
of GemOx was generally well tolerated. There were no
treatment-related deaths. No patients discontinued treatment
because of toxicity.
discussion
No effective standard therapy is yet available for advanced
biliary tract cancer. Only relatively small phase II trials have
assessed the efficacy and toxicity profiles of chemotherapy
regimens in the palliative treatment of gall-bladder cancer and
cholangiocarcinoma. Due to tumor-specific complications, such
as obstructive jaundice with impaired hepatic metabolism and
biliary excretion, toxicity profiles of chemotherapy regimens
may be different in gall-bladder and biliary tract carcinoma
compared with other cancers. Single-agent and multiagent
regimens have yielded modest results in patients with advanced
biliary carcinomas. Overall response rates and disease control
rates are about 25% (mostly 13%–35%, range 0%–64%). With
regard to combination therapy, Table 4 summarizes the most
recent trials in advanced biliary tract cancer [11, 12, 24–33].
Preclinical results of previous studies have demonstrated that
the difluorinated analogue of deoxy-cytidine difluoro-29,29-
deoxycytidine gemcitabine (GEM), synergistically interacts with
oxaliplatin in terms of anti-tumor activity in vitro [15, 16].
Moreover Mouvradis et al. [20] demonstrated the feasibility and
safety of gemcitabine–oxaliplatin (GEM–OX) combination
chemotherapy in a phase I study involving patients with
advanced solid tumors: the maximum tolerated dose was not
reached, the combination was well tolerated with a manageable
toxicity of doses up to 1400 mg/m2 of gemcitabine on days 1 and
8 and doses up to 120 mg/m2 of oxaliplatin.
Based on the important data on pancreatic cancer, Andre
et al. verified the activity and tolerability gemcitabine–
oxaliplatin (GEM–OX) combination in 33 patients with
advanced biliary tract adenocarcinoma. All received
gemcitabine 1000 mg/m2 as a 10 mg/m2/min infusion on day 1,
followed by oxaliplatin 100 mg/m2 as a 2-h infusion on
day 2, every 2 weeks. Tumor sites were gall-bladder (9 patients),
extrahepatic bile ducts (5 patients), ampulla of vater (3 patients)
and intrahepatic bile ducts (7 patients). National Cancer
Institute Common Toxicity Criteria grade 3–4 toxicities were
neutropenia 14% of patients, thrombocytopenia 9%, nausea/
vomiting 5% and peripheral neuropathy 7% [14].
Our experience is slightly different from this: the schedule of
treatment was different with gemcitabine administered on days
1 and 8 and oxaliplatin on day 1 after gemcitabine every 3 weeks.
The lower toxicity observed in our study is probably due to this
different schedule of treatment. Median survival achieved by our
patients was 12 months and therefore in the range of most other
Table 1. Patient characteristics
Characteristic No. of patients
(n = 24)
Disease
Metastatic 10
Locally advanced 14
Bile ducts 15
Gall-bladder 9
Sex
Female 14
Male 10
Age, years
Median 62
Range 38–75
ECOG performance status at baseline
0 13
1 7
2 4
Biliary stent or bypass 8
Prior therapy
Primary resection 12
Adjuvant chemoradiation 0
ECOG, Eastern Cooperative Oncology Group.
Table 2. Best overall tumor response
Tumor type CR PR SD PD ORR + SD
Disease Control
No. % No. % No. % No. % No. %
Total, all types
(n = 24)
1 4 11 45 5 20 7 29 17 70
Bile ducts
cancers (n = 15)
1 6 7 46 3 20 4 26 11 73
Gall-bladder
cancer (n = 9)
0 0 4 44 2 22 2 22 6 66
CR, complete response; PR, partial response; SD, stable disease for
minimum of three cycles; PD, progressive disease; ORR, objective
response rate.
Table 3. Toxicity in any cycle
Toxicity Grade 1–2 Grade 3 Grade 4
No. of
patients
% No. of
patients
% No. of
patients
%
Neutropenia 7 29 3 12 0 0
Anemia 0 0 0 0 0 0
Thrombocytopenia 3 12 3 12 0 0
Sensory neurophaty 8 33 2 8 0 0
Fatigue 11 45 5 20 0 0
Nausea/vomiting 6 25 1 4 0 0
Mucositis 3 12 0 0 0 0
Diarrhea 2 8 0 0 0 0
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studies investigating combination chemotherapy for biliary tract
cancer. Progression-free survival was similar to other published
data of phase II trials in biliary tract cancer (Table 4). We
observed no difference in survival and toxicity in patients with
gall-bladder and bile ducts cancers.
The prolongation of overall survival may be influenced by the
possibility of administering a 5-FU based second-line
chemotherapy Another important fact to outline is the
impressive rate of control disease in both groups of patients and
the possibility of surgery in two responding patients with locally
advanced disease. It would be interesting to have more data
about a comparison between single-agent chemotherapy versus
combination therapy in terms of benefit on quality of life and
survival. However, such randomized studies are very difficult to
carry out for the elevated number of patients requested and for
the difficulties in the patients’ selection.
In conclusion, combination chemotherapy with gemcitabine
and oxaliplatin seems to be a very promising regimen with
tolerable toxicity in advanced biliary tract cancers. Further
randomized studies comparing gemcitabine monotherapy with
gemcitabine oxaliplatin combination therapy are warranted to
identify the standard of treatment.
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